Management of a patient with unintended intravenous dihydroergotamine infusion extravasation causing brachial artery vasospasm
- PMID: 37091758
- PMCID: PMC10120444
- DOI: 10.1080/08998280.2023.2167187
Management of a patient with unintended intravenous dihydroergotamine infusion extravasation causing brachial artery vasospasm
Abstract
We present a patient being treated with intravenous dihydroergotamine (DHE) complicated by brachial artery vasospasm secondary to extravasation of DHE from an infiltrated peripheral intravenous catheter. She subsequently developed symptomatic vasospasm of the brachial artery, which ultimately required surgical intervention. Severe vasospasm remains a rare but serious risk of intravenous DHE extravasation, but there is currently limited data on proper management of this complication. This case report documents our management that led to full recovery of the patient. We recommend the use of reliable catheters for DHE infusions and prompt vascular surgery consult if there is suspicion for unintended extravasation.
Keywords: Brachial artery vasospasm; case report; dihydroergotamine extravasation.
Copyright © 2023 Baylor University Medical Center.
Conflict of interest statement
No funding or potential conflict of interest was reported by the authors. Consent was obtained from the patient for publication of this case.
Figures


Similar articles
-
Brachial Artery Vasospasm From Sequential Use of Intravenous Promethazine and Dihydroergotamine for Treatment of Status Migrainosus: A Case Report.Neurohospitalist. 2023 Apr;13(2):196-199. doi: 10.1177/19418744231153478. Epub 2023 Mar 23. Neurohospitalist. 2023. PMID: 37064942 Free PMC article.
-
Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data.Br J Clin Pharmacol. 2001 Jul;52(1):45-51. doi: 10.1046/j.0306-5251.2001.01415.x. Br J Clin Pharmacol. 2001. PMID: 11453889 Free PMC article. Clinical Trial.
-
DHE-Induced Peripheral Arterial Vasospasm in Primary Raynaud Phenomenon: Case Report.Neurohospitalist. 2019 Apr;9(2):113-115. doi: 10.1177/1941874418797764. Epub 2018 Sep 11. Neurohospitalist. 2019. PMID: 30915191 Free PMC article.
-
Is the Generally Held View That Intravenous Dihydroergotamine Is Effective in Migraine Based on Wrong "General Consensus" of One Trial? A Critical Review of the Trial and Subsequent Quotations.Headache. 2016 Oct;56(9):1482-1491. doi: 10.1111/head.12904. Epub 2016 Sep 6. Headache. 2016. PMID: 27595607 Review.
-
Dihydroergotamine (DHE) - Then and Now: A Narrative Review.Headache. 2020 Jan;60(1):40-57. doi: 10.1111/head.13700. Epub 2019 Nov 17. Headache. 2020. PMID: 31737909 Free PMC article.
References
-
- Lexicomp . Dihydroergotamine: Drug information. In: Post TW, ed. UpToDate. 2022. https://www.uptodate.com/contents/dihydroergotamine-drug-information. Accessed June 6, 2022.
-
- D.H.E . 45 (Dihydroergotamine mesylate) [package insert]. US Food and Drug Administration. Updated August 2008. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/005929s044lbl.pdf. Accessed June 6, 2022.
Publication types
LinkOut - more resources
Full Text Sources